Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant Help Center Crisis
Powered By
Real members of MyAmyloidosisTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

When being treated for ATTR Amyloidosis what is the difference between Avuttra or Vyndamax

A MyAmyloidosisTeam Member asked a question 💭
Chicopee, MA
September 16
 · 
Reactions
A MyAmyloidosisTeam Member

AI answer is a bit misleading and therefore incorrect. Amvuttra stops production of up to 88% of the liver's production of TTR. The liver is where 90% of your body's production of transthyretin occurs. Up to 5% of Transthyretin is produced in the choroid plexus part of your brain. Up to 5% is produced in your eyes.

Vyndamax, (Tafadamis) and Attruby (acoramidis) are protein stablizer drugs. They both prevent some (Vyndamax) or most of (Attruby) the Transthyretin proteins from coming apart. hATTR (130 different genes) does result in abnormal protein production

Wild type ATTR does not involve abnormal Transthyretin production. The tetrameric Transthyretin protein falls apart for reasons as yet unknown. Age, inflammation, or many other causes may be responsible for wtATTR.

September 27
A MyAmyloidosisTeam Member

Is it better to be treated with AVUTTRA

September 16
MyAmyloidosisTeam

Great question! Amvuttra (vutrisiran) and Vyndamax (tafamidis) are both used in ATTR amyloidosis treatment, but they work in very different ways.

Amvuttra belongs to a class called RNA interference (RNAi) therapies. It works by blocking the production of abnormal TTR protein before it can build up and cause harm. Think of it Show Full Answer

Great question! Amvuttra (vutrisiran) and Vyndamax (tafamidis) are both used in ATTR amyloidosis treatment, but they work in very different ways.

Amvuttra belongs to a class called RNA interference (RNAi) therapies. It works by blocking the production of abnormal TTR protein before it can build up and cause harm. Think of it like turning off a faucet before a flood starts. It is approved for:

- Polyneuropathy (nerve damage) from hereditary ATTR amyloidosis
- Cardiomyopathy (heart muscle disease) from both wild-type and hereditary ATTR amyloidosis

It is given as an injection under the skin once every three months by a healthcare professional. Vyndamax works differently — instead of stopping TTR protein production, it stabilizes the TTR protein so it is less likely to misfold and form amyloid deposits. It is approved specifically for cardiomyopathy in ATTR amyloidosis and is taken orally (as a pill).

A key caution with Vyndamax: allergic reactions are possible. Seek immediate medical attention if you experience:

- Trouble swallowing
- Hives or itchy skin rashes
- Chest tightness
- Fast heartbeat

The best choice between these two depends on your specific type of ATTR amyloidosis, symptoms, and overall health. Always discuss with your specialist to find the right fit for you.

September 16
A MyAmyloidosisTeam Member

Why is it better?

September 22

Related Questions

View All
What’s the Difference Between hATTR and Wild-Type ATTR?
Getting the Best Care for ATTR Amyloidosis
Understanding ATTR Amyloidosis